menu search

OMER / OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm

OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Omeros--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) on behalf of Omeros stockholders. Our investigation concerns whether Omeros has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 1, 2021, Omeros announced that the U.S. Food and Drug Admini Read More
Posted: Oct 7 2021, 22:30
Author Name: Business Wire
Views: 110681

OMER News  

Omeros to terminate kidney disease trial as therapy fails late-stage study

By Reuters
October 16, 2023

Omeros to terminate kidney disease trial as therapy fails late-stage study

Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of more_horizontal

Omeros Corporation - Still Looking Too Risky For A Buy Rating

By Seeking Alpha
July 21, 2023

Omeros Corporation - Still Looking Too Risky For A Buy Rating

Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's l more_horizontal

Omeros Announces Webcast Details for Annual Meeting of Shareholders

By Business Wire
June 21, 2023

Omeros Announces Webcast Details for Annual Meeting of Shareholders

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareh more_horizontal

Why Shares of Omeros Dropped on Monday

By The Motley Fool
June 12, 2023

Why Shares of Omeros Dropped on Monday

The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash. more_horizontal

Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 9, 2023

Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations G more_horizontal

Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 13, 2023

Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relatio more_horizontal

Why Omeros Stock Bolted Higher This Week

By The Motley Fool
February 9, 2023

Why Omeros Stock Bolted Higher This Week

A $200 million milestone payment sparked a rally in the biopharma's shares this week. more_horizontal

Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy

By Seeking Alpha
February 8, 2023

Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy

Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang som more_horizontal


Search within

Pages Search Results: